BT-GSI

• Description:

  BT-GSI is a γ-secretase inhibitor (GSI) and a bone-targeted Notch inhibitor. BT-GSI has dual anti-myeloma and anti-resorptive properties, which can be used for the research of multiple myeloma and associated bone disease. BT-GSI inhibits tumor growth and osteolytic disease progression[1].

• UNSPSC:

  12352005

• Target:

  Notch; γ-secretase

• Type:

  Reference compound

• Related Pathways:

  Neuronal Signaling; Stem Cell/Wnt

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bt-gsi.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=P(O)(O)C(P(O)(O)=O)NC(CCCN(C)/N=C/[C@H](CC(C)C)NC([C@H]([C@@H](C)CC)NC(OCC1=CC=CC=C1)=O)=O)=O.Br

• Molecular Formula:

  C26H46BrN5O10P2

• Molecular Weight:

  730.52

• References & Citations:

  [1]Hayley M Sabol, et al. Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity. Cancer Res. 2021 Oct 1;81 (19) :5102-5114.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported